Trial Profile
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Napabucasin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms CanStem111P
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 15 Aug 2020 This trial has been completed in Belgium (Global date of the end of the trial: 2020-03-29 and Czech Republic).